TRACON Pharmaceuticals Inc TCON
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TCON is a good fit for your portfolio.
News
-
TRACON Pharmaceuticals Announces Reverse Stock Split
-
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned
-
Thinking about buying stock in BigBear.ai, MicroCloud Hologram, TRACON Pharmaceuticals, Spruce Biosciences, or Recursion Pharmaceuticals?
-
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
-
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
Trading Information
- Previous Close Price
- $1.81
- Day Range
- $1.80–1.94
- 52-Week Range
- $1.59–14.80
- Bid/Ask
- $1.84 / $1.92
- Market Cap
- $4.23 Mil
- Volume/Avg
- 261,679 / 249,092
Key Statistics
- Price/Earnings (Normalized)
- 4.10
- Price/Sales
- 0.25
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.traconpharma.com
Valuation
|
Metric
|
TCON
|
|---|---|
Price/Earnings (Normalized) | 4.10 |
Price/Book Value | — |
Price/Sales | 0.25 |
Price/Cash Flow | 0.52 |
Price/Earnings
TCON
Financial Strength
|
Metric
|
TCON
|
|---|---|
Quick Ratio | 0.84 |
Current Ratio | 0.89 |
Interest Coverage | 0.51 |
Quick Ratio
TCON
Profitability
|
Metric
|
TCON
|
|---|---|
Return on Assets (Normalized) | 6.35% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
TCON
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ypythgknq | Xjn | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zwbjylq | Pygvrm | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Shvjpjh | Wfzpdx | $103.7 Bil | |
MRNA
| Moderna Inc | Yqrnfvkx | Tqvy | $47.9 Bil | |
ARGX
| argenx SE ADR | Rdhwxkxw | Hhhv | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Xjnfxvttc | Pqlsr | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dmtktckh | Ppqbvn | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dltqjgpgh | Rptdp | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cjswrgxbkx | Fmdgc | $12.8 Bil | |
INCY
| Incyte Corp | Wjttsmpx | Nhhqls | $12.1 Bil |